Proteins

KH-CB20

Cat. No.: HY-12828A CAS No.: 1354448-60-4 Molecular Formula: $C_{15}H_{13}Cl_2N_3O_2$

Molecular Weight: 338.19 Target: CDK; DYRK

Pathway: Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK

Powder -20°C Storage: 3 years

In solvent

2 years -80°C 6 months

-20°C 1 month

$$CI$$
 N
 O
 H_2N
 N

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (295.69 mM; Need ultrasonic and warming)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.9569 mL	14.7846 mL	29.5692 mL
	5 mM	0.5914 mL	2.9569 mL	5.9138 mL
	10 mM	0.2957 mL	1.4785 mL	2.9569 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.39 mM); Suspended solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution

BIOLOGICAL ACTIVITY

Description KH-CB20, an E/Z mixture, is a potent and selective inhibitor of CLK1 and the closely related isoform CLK4, with an IC₅₀ of 16.5 nM for CLK1. KH-CB20 can also inhibit DYRK1A (IC₅₀=57.8 nM) and CLK3 (IC₅₀=488 nM) $^{[1]}$.

IC₅₀ & Target CLK1 DYRK1A CLK3

> 57.8 nM (IC₅₀) 16.5 nM (IC₅₀) 488 nM (IC₅₀)

In Vitro KH-CB20 shows selectivity for CLK1 (IC₅₀=16.5 nM) over DYRK1A (IC₅₀=57.8 nM) and CLK3 (IC₅₀=488 nM)^[1].

REFERENCES			
[1]. Fedorov O, et, al. Specific Cl	_K inhibitors from a novel chemotype for regulatio	on of alternative splicing. Chem Biol. 2011 Jan 28;18((1):67-76.
	Caution: Product has not been fully valida	ted for medical applications. For research use	only
	Tel: 609-228-6898 Fax: 609-228-5		
		Q, Monmouth Junction, NJ 08852, USA	

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Page 2 of 2 www.MedChemExpress.com